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DEVICE ADVICE FROM THE FDA
Friday, June 24, 2011
HRPO Conference Room
22 N. Euclid Ave., Ste. 233
AGENDA:
8:30 am – 10:30 am
Device Advice
Lynn Henley, Center for Devices and Radiological Health
Ms. Henley has degrees in Biology, Biotechnology and Business. She has spoken to numerous
groups at academic institutions (Stanford University, University of Pittsburgh Medical Center),
conferences (Columbia University IRB Conference, MD&M West), government research
facilities (National Institutes of Health, Fort Detrick) and regulatory workshops (Regulatory
Affairs Professional Society, AdvaMed) concerning Investigational Device Exemptions and
Humanitarian Device Exemptions. At CDRH, she serves on the Clinical Expert Review
Committee, participate in the Level of Evidence Project, and represent the Office of Device
Evaluation at CDISC.
Topic for IRB staff and members (2 hours)
Case Study questions around:
• How to distinguish when “standard care” use of a device is research.
• Determining if a device is “exempt” from the IDE regulations
• When using a device for an approved indication, when does it become investigational?
Who determines whether the use is consistent with FDA approval? Where is this
information found?
• Who makes first determination regarding risk – FDA or IRB? If the IRB is the one making
the first determination regarding risk can or will this be overturned by the FDA?
• What is the Pre-IDE application? What does it look like? How is this used in an IRB
review?
• Off-label use of devices. Are they always treated as investigational devices?
• Off-label use of devices cleared for marketing under a 510K. Is there more than one type
of 510Kclearance? Does the 510K act as an approval for research purposes?
• Off-label use of a significant-risk device. Is an IDE needed? Are there other
requirements? What is the investigators’ responsibility? What is the IRB’s responsibility?
• When a study is just collecting data on an approved device do risk determinations
apply? Does off-label use apply?
• Humanitarian Use Devices
o Responsibilities of the IRB and investigator when there is a Premarket Approval
o Responsibilities of the IRB and investigator when there is not a Premarket
Approval
o What is a Premarket approval?
o FDA wants additional safety data on a HUD. What does this mean? Is this
research? Responsibilities of the investigator and IRB.
• Transitional Devices – what are they?
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CASE STUDIES
1. An investigator wants to compare the effectiveness of two mesh reinforcement devices
in preventing leaks after liver surgery. One device is approved by the FDA for use in
liver surgery. The other device has a 510k clearance for use in “soft tissue”. The
investigator claims both devices are approved for use in liver surgery.
Questions: How much flexibility does the IRB have in determining if the requested use
falls under the 510k clearance or FDA approval? Must the 510k state the specific organ,
in this case, the liver? Or is the term “soft tissue” sufficient?
2. An investigator proposes a prospective longitudinal study of biologic mesh prosthetics
used during gastric bypass surgery. The study will allow surgeons to use their preferred
biologic mesh. If the surgeon has no preference they will use Company X’s mesh
product. The study is funded by the Company X. Company X’s mesh product is
approved for this use under a 510K. This study will allow the investigator to assess the
use and efficacy of Company X’s mesh product compared to other similar products.
Questions: Does Company X’s device require an IDE in this scenario? In general, if an
investigator wants to assess the safety and/or efficacy of an approved device, being
used for the approved indications, is an IDE ever required? If yes, under what
circumstances? What if the study only involved use of Company X’s device and the
collection of safety and/or efficacy data?
3. An investigator is conducting a study to better understand a genetic disorder that greatly
decreases a person’s ability to sweat. One test that will be performed as part of the
study utilizes a device that measures the amount of sweat produced on a specified area
of the skin. There is no therapeutic of diagnostic intervention in this study. The device is
approved to measure sweat production for the diagnosis of cystic fibrosis. However,
there is no mention of approval to measure sweat production in individuals with this
genetic disorder.
Questions: Is this considered an investigational device? Does the IRB need to
determine if the device is SR or NSR? Are there other considerations for the IRB when
reviewing studies using devices to collect physiologic data? Is this study regulated by
the FDA?
4. A device company that manufactures surgical forceps would like to perform usability and
preference testing on their angled and straight forceps. Information about the surgeon’s
experience and preferences will be collected along with information about the patients
undergoing the surgery. Both surgical forceps are approved by the FDA.
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Questions: Are the forceps considered investigational devices in this instance? Is a
SR/NSR determination required by the IRB? Is this study regulated by the FDA? How
does the IRB differentiate between consumer preference testing and the collection of
efficacy data?
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